1-tert-butylphospholane | 108568-39-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 金属杂环化合物
• 英文名称: 1-tert-butylphospholane
• 英文别名: 1-t-butylphosphacyclopentane；Phospholane, 1-(1,1-dimethylethyl)-
• CAS: 108568-39-4
• 化学式: C₈H₁₇P
• 分子量: 144.197
• InChiKey: UFSZDRZMKJSOOM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  acetylacetonatodicarbonylrhodium(l) 、 1-tert-butylphospholane 以 乙醚 为溶剂， 以82%的产率得到carbonyl(2,4-pentanedionato-O)bis(1-t-butylphosphacyclopentane)rhodium(I)
  参考文献：
  名称：

  Yoshida, Shin-ichi; Ohgomori, Yuji; Watanabe, Yoshihisa, Journal of the Chemical Society, Dalton Transactions, 1988, p. 895 - 898

  摘要：

  DOI：
• 作为产物：
  描述：

  叔丁基锂 、 1,4-dilithiobutane 在 三甲氧基磷 作用下， 生成 1-tert-butylphospholane
  参考文献：
  名称：

  A One-Step Synthesis of 1,4-Bis(1-phospholano)butane

  摘要：

  标题化合物 2 是通过亚磷酸三甲酯与 1,4-二硫代丁烷反应制备的，收率很高。通过与烷基二甲氧基膦衍生物 3 反应，可以用类似的方法制备单端 1-烷基化磷脂 4。

  DOI：

  10.1055/s-1993-25785

文献信息

• Ligand Stereoelectronic Effects in Complexes of Phospholanes, Phosphinanes, and Phosphepanes and Their Implications for Hydroformylation Catalysis
  作者：R. Angharad Baber、Mairi F. Haddow、Ann J. Middleton、A. Guy Orpen、Paul G. Pringle、Anthony Haynes、Gary L. Williams、Rainer Papp

  DOI：10.1021/om060912v

  日期：2007.1.1

  Convenient syntheses are described for the five-, six-, and seven-membered phosphacycles PhP(CH2)x-1, where x = 5 (La5), 6 (La6), 7 (La7), and ButP(CH2)x-1 where x = 5 (Lb5), 6 (Lb6), 7 (Lb7). Treatment of [PtCl2(cod)] with La5-7 gives cis-[PtCl2(La5-7)2] (1a5-7), whereas with Lb5-7 a mixture of cis-[PtCl2(Lb5-7)2] (1b5-7) and trans-[PtCl2(Lb5-7)2] (2b5-7) is obtained. Metathesis of 1a7 with NaI gives

  描述了五元，六元和七元磷环PhP（CH 2）x -1的便捷合成方法，其中x = 5（L a5），6（ L a6），7（ L a7）和Bu t P（CH 2） x -1，其中x = 5（ L b5），6（ L b6），7（ L b7）。用L a处理[PtCl 2（cod）]5 - 7给出了顺式- [氯铂酸2（大号一个5 - 7） 2 ]（ 1A 5 - 7），而用大号b5 - 7的混合物的顺式- [氯铂酸2（大号b5 - 7） 2 ]（图1b 5 - 7）和反式- [氯铂酸2（大号b5 - 7） 2 ]（ 2B 5 - 7）被获得。1a 7与NaI复分解得到顺式[PtI 2（ L a7） 2 ]（ 3a 7）和反式[PtI 2（ L a7） 2 ]（ 4a 7）。的晶体结构1A 5， 1A 6， 1A 7，和图4a 7已被确定。比较1a 7和4a 7的结构可知L a7号具有可变的空间体积，晶体学确定的锥角范围为137°（小于L
• Compositions and methods for treating diseases and conditions
  申请人：University of Pittsburgh—Of the Commonwealth System of Higher Education

  公开号：US10487076B2

  公开（公告）日：2019-11-26

  A compound of Formula II, or a salt, ester, solvate, hydrate or prodrug thereof: where: X1 is a branched or unbranched C1-10 alkyl, (CH2)s—NH—(CH2)t, (CH2)s—O—(CH2)t, or (CH2)s—C(NH2)—(CH2)v—NH—(CH2)t, where s, t and v are each, independently an integer from 1 to 5; A and B are each, independently, C6-10aryl, C6-10aryl-C1-6alkyl, C3-9 heteroaryl, or C3-9heteroaryl-C1-6alkyl, each optionally substituted with 1, 2 or 3 independently selected Rg groups; C and D are each, independently, C3-7 cycloalkyl, C3-7 cycloalkyl-C1-6alkyl, C3-7 heterocycloalkyl, C3-7 heterocycloalkyl-C1-6 alkyl, C6-10aryl, C6-10aryl-C1-6alkyl, C3-9 heteroaryl, or C3-9heteroaryl-C1-6alkyl, each optionally substituted with 1, 2 or 3 independently selected Rg groups; each Rg is, independently, halogen, C1-6 alkyl, C1-6 haloalkyl, hydroxyl, C1-6 alkoxy, C1-6 haloalkoxy, amino, C1-6 alkylamino, or di-C1-6alkylamino; and n1 and p1 are each, independently, integers from 1 to 10.

  式 II 的化合物或其盐、酯、溶液、水合物或原药： 其中 X1 是支链或未支链的 C1-10 烷基、(CH2)s-NH-(CH2)t、(CH2)s-O-(CH2)t 或 (CH2)s-C(NH2)-(CH2)v-NH-(CH2)t ，其中 s、t 和 v 各自独立地为 1 至 5 的整数； A 和 B 各自独立为 C6-10 芳基、C6-10 芳基-C1-6烷基、C3-9 杂芳基或 C3-9 杂芳基-C1-6烷基，各自任选被 1、2 或 3 个独立选择的 Rg 基团取代； C 和 D 各自独立为 C3-7 环烷基、C3-7 环烷基-C1-6烷基、C3-7 杂环烷基、C3-7 杂环烷基-C1-6烷基、C6-10 芳基、C6-10 芳基-C1-6烷基、C3-9 杂芳基或 C3-9 异芳基-C1-6烷基，各自任选被 1、2 或 3 个独立选择的 Rg 基团取代； 每个 Rg 独立地是卤素、C1-6 烷基、C1-6 卤代烷基、羟基、C1-6 烷氧基、C1-6 卤代烷氧基、氨基、C1-6 烷基氨基或二-C1-6 烷基氨基；以及 n1 和 p1 各自独立地为 1 至 10 的整数。
• Chiral metal complex compounds
  申请人：Hoffmann-La Roche Inc.

  公开号：US11124532B2

  公开（公告）日：2021-09-21

  The invention comprises novel chiral metal complex compounds of the formula wherein M, PR2, R3 and R4 are outlined in the description, its stereoisomers, in the form as a neutral complex or a complex cation with a suitable counter ion. The chiral metal complex compounds can be used in asymmetric reactions, particularly in asymmetric reductions of ketones, imines or oximes.

  本发明包括式如下的新型手性金属配合物化合物 其中 M、PR2、R3 和 R4 在描述中概述，其立体异构体的形式为中性络合物或与适当反离子的络阳离子。手性金属络合物可用于不对称反应，尤其是酮、亚胺或肟的不对称还原反应。
• COMPOSITIONS AND METHODS FOR TREATING DISEASES AND CONDITIONS
  申请人：University of Pittsburgh - Of the Commonwealth System of Higher Education

  公开号：US20180134693A1

  公开（公告）日：2018-05-17

  A compound of Formula II, or a salt, ester, solvate, hydrate or prodrug thereof: where: X 1 is a branched or unbranched C 1-10 alkyl, (CH 2 ) s —NH—(CH 2 ) t , (CH 2 ) s —O—(CH 2 ) t , or (CH 2 ) s —C(NH 2 )—(CH 2 ) v —NH—(CH 2 ) t , where s, t and v are each, independently an integer from 1 to 5; A and B are each, independently, C 6-10 aryl, C 6-10 aryl-C 1-6 alkyl, C 3-9 heteroaryl, or C 3-9 heteroaryl-C 1-6 alkyl, each optionally substituted with 1, 2 or 3 independently selected R g groups; C and D are each, independently, C 3-7 cycloalkyl, C 3-7 cycloalkyl-C 1-6 alkyl, C 3-7 heterocycloalkyl, C 3-7 heterocycloalkyl-C 1-6 alkyl, C 6-10 aryl, C 6-10 aryl-C 1-6 alkyl, C 3-9 heteroaryl, or C 3-9 heteroaryl-C 1-6 alkyl, each optionally substituted with 1, 2 or 3 independently selected R g groups; each R g is, independently, halogen, C 1-6 alkyl, C 1-6 haloalkyl, hydroxyl, C 1-6 alkoxy, C 1-6 haloalkoxy, amino, C 1-6 alkylamino, or di-C 1-6 alkylamino; and n 1 and p 1 are each, independently, integers from 1 to 10.
• CHIRAL METAL COMPLEX COMPOUNDS
  申请人：Hoffmann-La Roche Inc.

  公开号：US20200040021A1

  公开（公告）日：2020-02-06

  The invention comprises novel chiral metal complex compounds of the formula wherein M, PR 2 , R 3 and R 4 are outlined in the description, its stereoisomers, in the form as a neutral complex or a complex cation with a suitable counter ion. The chiral metal complex compounds can be used in asymmetric reactions, particularly in asymmetric reductions of ketones, imines or oximes.